Corcept names Justin Gunn president of endocrinology as Sean Maduck retires

• Corcept named Justin Gunn president of its Endocrinology division, effective Oct. 1, succeeding retiring Sean Maduck.
• Gunn will join the executive team, reporting to CEO Joseph K. Belanoff.
• Maduck will stay on as a senior commercial advisor.
• Gunn joined Corcept in July 2024 as VP of Sales and Commercial Learning in Oncology.
• He previously spent nearly 18 years at Gilead, leading sales teams across cardiovascular, respiratory, oncology, virology; earlier roles at Merck, Sepracor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202609230800BIZWIRE_USPR_____20260923_BW150844) on September 23, 2026, and is solely responsible for the information contained therein.